NeuroBo Pharmaceuticals announces data from SAD Part 1 of trial of DA-1726

NeuroBo Pharmaceuticals announced positive top-line safety, tolerability, and dose-linear pharmacokinetics, PK, data from the single ascending dose, SAD, Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin, OXM, analog agonist that functions as a glucagon-like peptide-1 receptor, GLP1R, and glucagon receptor, GCGR, for the treatment of obesity. In the SAD Part 1 of the Phase 1 clinical trial, a total of 45 obese, otherwise healthy participants were randomized in a double-blind, 6:3 ratio of DA-1726 or placebo. Single ascending doses were found to be safe and well tolerated, with no serious adverse events. Only 5 subjects in the DA-1726 treatment group reported adverse events compared with 3 subjects in the placebo group. A dose-linear PK profile was observed across the investigated dose range. Additional cohorts are being added to the SAD Part 1 to explore the maximum tolerated dose.